The primary objective of this study is to obtain de-identified, clinically characterized, whole blood specimens to evaluate biomarkers associated with cancer for diagnostic assay development.
Subjects will have been recently diagnosed with an untreated hematologic malignancy. Subjects will have a blood sample collected at enrollment and provide medical history prior to initiation of treatment. There will be no further follow-up.
Study Type
OBSERVATIONAL
Enrollment
409
Subjects participating in the study will have blood drawn at enrollment.
Blood-based biomarkers associated with genetic and epigenetic alterations.
Biomarkers under evaluation include differential methylation of nucleic acids and altered expression of proteins in blood from subjects with a hematologic malignancy at the pre-intervention stage.
Time frame: Point in time blood collection (1 day) at enrollment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Mercy Fort Smith
Fort Smith, Arkansas, United States
CARTI Cancer Center
Little Rock, Arkansas, United States
Marin Cancer Care
Greenbrae, California, United States
Alliance Research Centers
Laguna Hills, California, United States
North County Oncology
Oceanside, California, United States
Middlesex Hospital
Middletown, Connecticut, United States
The Stamford Hospital
Stamford, Connecticut, United States
Mid-Florida Hematology and Oncology Center
Orange City, Florida, United States
PMG Research, INC
Downers Grove, Illinois, United States
Illinois CancerCare-Peoria
Peoria, Illinois, United States
...and 25 more locations